Trial Profile

A Phase 3, Multicenter, Double-Masked, Randomized, 3-Arm Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTXTKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Nov 2025 According to an Ocular Therapeutix media release, company announced that the first patient has been randomized in the trial.
07 Nov 2025 New trial record
30 Sep 2025 According to an Ocular Therapeutix media release, company announced the pricing of an underwritten offering and expects to use the net proceeds, together with its existing cash and cash equivalents, to fund its planned open-label extension study of AXPAXLI in patients with wet age-related macular degeneration (wet AMD), as well as its planned phase 3 clinical trials of AXPAXLI for the treatment of non-proliferative diabetic retinopathy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com